Construction of a Novel Liver-Targeting Fusion Interferon by Incorporation of a Plasmodium Region I-Plus Peptide
暂无分享,去创建一个
[1] M. Levrero,et al. IFN-α inhibits HBV transcription and replication in cell culture and in humanized mice by targeting the epigenetic regulation of the nuclear cccDNA minichromosome. , 2012, The Journal of clinical investigation.
[2] H. Mei,et al. Expression of a novel dual-functional protein--the antimicrobial peptide LL-37 fused with human acidic fibroblast growth factor in Escherichia coli. , 2012, Protein expression and purification.
[3] Yun Bai,et al. An efficient and rapid method for cDNA cloning from difficult templates using codon optimization and SOE-PCR: with human RANK and TIMP2 gene as examples , 2011, Biotechnology Letters.
[4] H. Mei,et al. Expression of the antimicrobial peptide cecropin fused with human lysozyme in Escherichia coli , 2010, Applied Microbiology and Biotechnology.
[5] Marina Etcheverrigaray,et al. Highly glycosylated human alpha interferon: An insight into a new therapeutic candidate. , 2010, Journal of biotechnology.
[6] R. A. Ningrum,et al. Construction of synthetic open reading frame encoding human interferon alpha 2b for high expression in Escherichia coli and characterization of its gene product. , 2010, Journal of biotechnology.
[7] S. Padmanabhan,et al. Expression and Purification of SAK-fused Human Interferon Alpha in Escherichia coli , 2009 .
[8] Y. Jeong,et al. Superparamagnetic Iron Oxide Nanoparticles Coated with Galactose-Carrying Polymer for Hepatocyte Targeting , 2008, Journal of biomedicine & biotechnology.
[9] E. Winzeler,et al. Plasmodium Circumsporozoite Protein Promotes the Development of the Liver Stages of the Parasite , 2007, Cell.
[10] Prabhakar Tiwari,et al. Amplification of GC-rich genes by following a combination strategy of primer design, enhancers and modified PCR cycle conditions. , 2007, Molecular and cellular probes.
[11] Amine Sadok,et al. A strategy for high-level expression of soluble and functional human interferon alpha as a GST-fusion protein in E. coli. , 2007, Protein engineering, design & selection : PEDS.
[12] Ana Rodriguez,et al. The silent path to thousands of merozoites: the Plasmodium liver stage , 2006, Nature Reviews Microbiology.
[13] T. McCutchan,et al. An Immunologically Cryptic Epitope of Plasmodium falciparum Circumsporozoite Protein Facilitates Liver Cell Recognition and Induces Protective Antibodies That Block Liver Cell Invasion* , 2005, Journal of Biological Chemistry.
[14] D. Prazeres,et al. Translational Features of Human Alpha 2b Interferon Production in Escherichia coli , 2004, Applied and Environmental Microbiology.
[15] P. Ho,et al. Overexpression of a synthetic gene encoding human alpha interferon in Escherichia coli. , 2004, Protein expression and purification.
[16] R. Kisilevsky,et al. A Binding Site for Highly Sulfated Heparan Sulfate Is Identified in the N Terminus of the Circumsporozoite Protein , 2004, Journal of Biological Chemistry.
[17] L. Young,et al. Two-step total gene synthesis method. , 2004, Nucleic acids research.
[18] A. Holder,et al. Function of Region I and II Adhesive Motifs ofPlasmodium falciparum Circumsporozoite Protein in Sporozoite Motility and Infectivity* , 2002, The Journal of Biological Chemistry.
[19] Ana Rodriguez,et al. Invasion of mammalian host cells by Plasmodium sporozoites , 2002, BioEssays : news and reviews in molecular, cellular and developmental biology.
[20] Y. Ikada,et al. Liver targeting of interferon-beta with a liver-affinity polysaccharide based on metal coordination in mice. , 2001, The Journal of pharmacology and experimental therapeutics.
[21] M. Bertini,et al. Liver targeting of antiviral nucleoside analogues through the asialoglycoprotein receptor , 1997, Journal of viral hepatitis.
[22] P. Vajro,et al. Side effects of alpha-interferon therapy and impact on health-related quality of life in children with chronic viral hepatitis. , 1997, The Pediatric infectious disease journal.
[23] T. J. Berkel,et al. Targeting Hepatitis B Therapy to the Liver , 1996 .
[24] T. V. van Berkel,et al. Targeting hepatitis B therapy to the liver. Clinical pharmacokinetic considerations. , 1996, Clinical pharmacokinetics.